{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:40:21Z","timestamp":1791826821307,"version":"4.3.4"},"reference-count":26,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Higher-risk myelodysplastic syndrome (HR-MDS) with RARA gene overexpression is a subset of patients (pts) with an actionable target for tamibarotene, an oral and a selective retinoic acid receptor-\u03b1 (RAR-\u03b1) agonist. Tamibarotene with azacitidine (AZA) showed complete remission (CR) rates in myeloid leukemia. SELECT-MDS-1 was a phase 3 study comparing the activity of tamibarotene + AZA to placebo + AZA in these pts with newly diagnosed HR-MDS with RARA overexpression. Eligible pts had confirmed RARA overexpression, untreated MDS with higher-risk features by revised International Prognostic Scoring System (IPSS-R), and marrow blast count &amp;gt;5%. Pts were randomized 2:1 to receive tamibarotene + AZA or placebo + AZA, respectively. A total of 246 participants were randomized with 164 and 82 in the tamibarotene + AZA and placebo + AZA groups, respectively. Baseline characteristics included: 69.9% male; median age 75 years (range, 38-93); primary MDS, 89.8%; MDS-excess blasts-1, 48% and MDS-excess blasts-2, 52%; and IPSS-R risk category intermediate (25.5%), high (35.7%), and very high (38.9%). The study did not meet the primary end point of CR, with a P value of .2084 for the treatment effect in the tamibarotene + AZA group. The CR rates were 23.81% and 18.75% in the tamibarotene + AZA and placebo + AZA groups, respectively. The use of tamibarotene-based therapy to target RAR-\u03b1 as a novel approach in pts with HR-MDS with RARA gene overexpression is not a paradigm, which can augment response rates beyond AZA monotherapy. Further explorations of alternative approaches, including those with a biomarker, to alter the natural history of this disease are warranted. This trial was registered at www.clinicaltrials.gov as #NCT04797780.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016229","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T14:34:18Z","timestamp":1746628458000},"page":"4090-4099","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS"],"prefix":"10.1182","volume":"9","author":[{"given":"Amy E.","family":"DeZern","sequence":"first","affiliation":[{"name":"1Johns Hopkins University, Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-2778","authenticated-orcid":false,"given":"Sylvain","family":"Thepot","sequence":"additional","affiliation":[{"name":"2Centre Hospitalier Universitaire, Hematology, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-4942","authenticated-orcid":false,"given":"Stephane","family":"de Botton","sequence":"additional","affiliation":[{"name":"3Institut Gustave Roussy, Department of Hematology, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-2906","authenticated-orcid":false,"given":"Andrea","family":"Patriarca","sequence":"additional","affiliation":[{"name":"4Hematology Unit, AOU Maggiore della Carit\u00e0 and University of Eastern Piedmont, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-2142","authenticated-orcid":false,"given":"Dries","family":"Deeren","sequence":"additional","affiliation":[{"name":"5AZ Delta, Department of Hematology, Roeselare, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5933-8562","authenticated-orcid":false,"given":"Jose-Miguel","family":"Torregrossa-Diaz","sequence":"additional","affiliation":[{"name":"6Centre Hospitalier Universitaire de Poitiers, University Hospital of Poitiers, Department of Hematology, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[{"name":"7Romagnolo Institute to Study Tumors \u201cDino Amadori,\u201d Department of Hematology, Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-513X","authenticated-orcid":false,"given":"Teresa","family":"Bernal","sequence":"additional","affiliation":[{"name":"8Hospital Universitario Central de Asturias, Department of Hematology, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8229-1208","authenticated-orcid":false,"given":"Juan","family":"Bergua Burgues","sequence":"additional","affiliation":[{"name":"9Hospital San Pedro de Alc\u00e1ntara, Department of Hematology, Caceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-1307","authenticated-orcid":false,"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[{"name":"10Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Deparment of Leukemia Research Institute, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0246-1524","authenticated-orcid":false,"given":"Anna","family":"Jon\u00e1\u0161ov\u00e1","sequence":"additional","affiliation":[{"name":"11Medical Department Hematology, Charles University General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"12Yale University and Yale Cancer Center, Division of Hematologic Maignancies, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dimicoli-Salazar","sequence":"additional","affiliation":[{"name":"13H\u00f4pital Haut-L\u00e9v\u00eaque, Centre Hospitalier Universitaire de Bordeaux, Hematology, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lestine","family":"Simand","sequence":"additional","affiliation":[{"name":"14Institut de Canc\u00e9rologie de Strasbourg Europe, Hematology, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valcarcel","sequence":"additional","affiliation":[{"name":"15Hospital Universitario Vall d'Hebron, Department of Hematology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-6779","authenticated-orcid":false,"given":"Maria","family":"Diez Campelo","sequence":"additional","affiliation":[{"name":"16Hospital Universitario de Salamanca, Institute of Biomedical Research of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxing","family":"Chai-Ho","sequence":"additional","affiliation":[{"name":"17Division of Hematology and Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3104-106X","authenticated-orcid":false,"given":"Lalit","family":"Saini","sequence":"additional","affiliation":[{"name":"18Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Garnier","sequence":"additional","affiliation":[{"name":"19Hematology Clinic, Nantes University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-7034","authenticated-orcid":false,"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[{"name":"20Hospital Hietzing, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-1337","authenticated-orcid":false,"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Shaarei Zedek Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Nagy","sequence":"additional","affiliation":[{"name":"22Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"23Department of Haematological Medicine, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[{"name":"24University of Freiburg Medical Center, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-8180","authenticated-orcid":false,"given":"Grzegorz","family":"Basak","sequence":"additional","affiliation":[{"name":"25Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3614","authenticated-orcid":false,"given":"Hetty E.","family":"Carraway","sequence":"additional","affiliation":[{"name":"26Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[{"name":"27Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-4962","authenticated-orcid":false,"given":"Uma","family":"Borate","sequence":"additional","affiliation":[{"name":"28Leukemia and Hematologic Malignancies Program, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-2172","authenticated-orcid":false,"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[{"name":"29MDS Unit, Department of Medical Sciences and Public Health, AOU Careggi, University of Florence, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Campbell","sequence":"additional","affiliation":[{"name":"30Lothian Health Board Western General Hospital in National Health Service Lothian, Edinburgh, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"31D\u00e9partement d\u2019H\u00e9matologie et Immunologie, Assistance Publique\u2013H\u00f4pitaux de Paris Nord Service d'H\u00e9matologie Seniors H\u00f4pital St Louis\/Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Braun","sequence":"additional","affiliation":[{"name":"32H\u00f4pital Avicenne, Assistance Publique\u2013H\u00f4pitaux de Paris Service H\u00e9matologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lanza","sequence":"additional","affiliation":[{"name":"33Ospedale Santa Maria delle Croci, Hematology, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-8936","authenticated-orcid":false,"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[{"name":"34Department of Haematology and Transplantology, Medical University of Gda\u0144sk University Clinical Center, Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Roth","sequence":"additional","affiliation":[{"name":"35Syros Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Paul","sequence":"additional","affiliation":[{"name":"35Syros Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pourab","family":"Roy","sequence":"additional","affiliation":[{"name":"35Syros Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kelly","sequence":"additional","affiliation":[{"name":"35Syros Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Volkert","sequence":"additional","affiliation":[{"name":"35Syros Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Chisholm","sequence":"additional","affiliation":[{"name":"35Syros Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya Abdul","family":"Malak","sequence":"additional","affiliation":[{"name":"35Syros Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia M.","family":"Klimek","sequence":"additional","affiliation":[{"name":"35Syros Pharmaceuticals, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[{"name":"36Centre Hospitalier Universitaire de Nice, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"12","key":"2025082609515102200_bib1","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41375-022-01724-9","article-title":"Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes","volume":"36","author":"Zeidan","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2025082609515102200_bib2","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.3390\/ijms24055018","article-title":"Understanding the continuum between high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"24","author":"Zavras","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2025082609515102200_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2025082609515102200_bib4","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1158\/1078-0432.CCR-22-3348","article-title":"Considerations for drug development in myelodysplastic syndromes","volume":"29","author":"Sekeres","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2025082609515102200_bib5","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/bloodadvances.2022008747","article-title":"An agenda to advance research in myelodysplastic syndromes: a top 10 priority list from the first international workshop in MDS","volume":"7","author":"Stahl","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2025082609515102200_bib6","first-page":"359","article-title":"AM 80, retinobenzoic acid, Tamibaro","volume":"5","author":"Tamibarotene","year":"2004","journal-title":"Drugs R D"},{"issue":"8","key":"2025082609515102200_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1358\/dot.2007.43.8.1072615","article-title":"Tamibarotene","volume":"43","author":"Miwako","year":"2007","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"2025082609515102200_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41375-018-0233-7","article-title":"Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study","volume":"33","author":"Takeshita","year":"2019","journal-title":"Leukemia"},{"issue":"14","key":"2025082609515102200_bib9","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.3390\/cancers15143535","article-title":"The promise of retinoids in the treatment of cancer: neither burnt out nor fading away","volume":"15","author":"Nagai","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2025082609515102200_bib10","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/bloodadvances.2022008806","article-title":"Targeting RARA overexpression with tamibarotene, a potent and selective RARalpha agonist, is a novel approach in AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2025082609515102200_bib11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"17","key":"2025082609515102200_bib12","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"14","key":"2025082609515102200_bib13","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"2025082609515102200_bib14","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"2025082609515102200_bib15","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast percentage AML","volume":"6","author":"Ades","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2025082609515102200_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol"},{"issue":"31","key":"2025082609515102200_bib17","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025082609515102200_bib18","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.2020010100","article-title":"Retinoids in hematology: a timely revival?","volume":"137","author":"Geoffroy","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025082609515102200_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/17474086.2023.2166923","article-title":"Advances in myelodysplastic syndromes: promising novel agents and combination strategies","volume":"16","author":"Madanat","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"15","key":"2025082609515102200_bib20","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"2025082609515102200_bib21","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/cells11142249","article-title":"Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes","volume":"11","author":"Abaza","year":"2022","journal-title":"Cells"},{"issue":"24","key":"2025082609515102200_bib22","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025082609515102200_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025082609515102200_bib24","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1080\/10428194.2023.2243356","article-title":"Use of tamibarotene, a potent and selective RARalpha agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression","volume":"64","author":"Stein","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025082609515102200_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.1986.4.4.589","article-title":"13-cis retinoic acid treatment for myelodysplastic syndromes","volume":"4","author":"Picozzi","year":"1986","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025082609515102200_bib26","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.11262","article-title":"Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes","volume":"92","author":"Siitonen","year":"2007","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4090\/2406461\/blooda_adv-2025-016229-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4090\/2406461\/blooda_adv-2025-016229-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T13:52:02Z","timestamp":1756216322000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/16\/4090\/537145\/Pivotal-results-of-SELECT-MDS-1-phase-3-study-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016229","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,26]]},"published":{"date-parts":[[2025,8,13]]}}}